Long Noncoding RNA ZFAS1 Promotes Progression of NSCLC via Regulating of miR-590-3p

Zhou, Yumei; Si, Lengge; Liu, Zihao; Shi, Yuting; Agula, B

doi:10.1177/0963689720919435

Cited by 10 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, we revealed that levels of CFHR3 were negatively and significantly associated with miR-590-3p levels in HCC tissues. Several studies show that miR-590-3p is a decisive prognostic marker for cancers, including HCC, colorectal cancer, and non-small cell lung cancer [ 28 – 30 ]. In our further study, the inhibition of CFHR3 mRNA levels by miR-590-3p was figured out.…”

Section: Discussionmentioning

confidence: 99%

The miR-590-3p/CFHR3/STAT3 signaling pathway promotes cell proliferation and metastasis in hepatocellular carcinoma

Wan

Luo

et al. 2022

Aging

View full text Add to dashboard Cite

Accumulating evidence has indicated that Complement factor H-related 3 (CFHR3) plays an essential role in various diseases. However, the biological functions of CFHR3 in hepatocellular carcinoma (HCC) remain largely unclear. Therefore, we perform a further study on CFHR3 in HCC. In this article, we report the suppressive role of CFHR3 in the proliferation and metastasis of HCC cells. CFHR3 downregulation is closely associated with large (T3-T4) HCC, tumor recurrence, and advanced (stage III-IV) clinical stage, functioning as an independent factor for the prognoses of HCC patients. Knockdown of CFHR3 promotes proliferation, migration, and invasion of HCC cells. Mechanistically, downregulation of CFHR3 is induced by miR-590-3p binding to the 3' untranslated region (UTR) of CFHR3. CFHR3 downregulation promotes the phosphorylation of STAT3 protein, thereby suppressing p53 expression. The promotional effect upon downregulation of CFHR3 induced by CFHR3 stable knockdown or miR-590-3p on HCC cell malignant phenotypes is attenuated by STAT3 inhibitor, S3I-201. In conclusion, our results reveal that CFHR3 is a protective biomarker for HCC patients, and targeting the miR-590-3p/CFHR3/p-STAT3/p53 signaling axis provides a promising strategy for HCC therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

The miR-590-3p/CFHR3/STAT3 signaling pathway promotes cell proliferation and metastasis in hepatocellular carcinoma

Wan

Luo

et al. 2022

Aging

View full text Add to dashboard Cite

show abstract

“…It has been found that lncRNA ZFAS1 inhibits mitotic cycle 42 expression through regulating miR-590-3p in NSCLC cells [35]. Moreover, several studies have shown that has-miR-590-3p is involved in tumor development in several cancers, including ovarian cancers, colorectal cancer, and renal clear cancer [36][37][38][39].…”

Section: Discussionmentioning

confidence: 99%

SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma

Zhang

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

Pulmonary surfactant protein A1 (SFTPA1) is a member of the C-type lectin subfamily that plays a critical role in maintaining lung tissue homeostasis and the innate immune response. SFTPA1 disruption can cause several acute or chronic lung diseases, including lung cancer. However, little research has been performed to associate SFTPA1 with immune cell infiltration and the response to immunotherapy in lung cancer. The findings of our study describe the SFTPA1 expression profile in multiple databases and was validated in BALB/c mice, human tumor tissues, and paired normal tissues using an immunohistochemistry assay. High SFTPA1 mRNA expression was associated with a favorable prognosis through a survival analysis in lung adenocarcinoma (LUAD) samples from TCGA. Further GeneOntology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses showed that SFTPA1 was involved in the toll-like receptor signaling pathway. An immune infiltration analysis clarified that high SFTPA1 expression was associated with an increased number of M1 macrophages, CD8+ T cells, memory activated CD4+ T cells, regulatory T cells, as well as a reduced number of M2 macrophages. Our clinical data suggest that SFTPA1 may serve as a biomarker for predicting a favorable response to immunotherapy for patients with LUAD. Collectively, our study extends the expression profile and potential regulatory pathways of SFTPA1 and may provide a potential biomarker for establishing novel preventive and therapeutic strategies for lung adenocarcinoma.

show abstract

“…Researchers and scholars have studied the mechanism: lncRNA MAGI2-AS3 inhibits the proliferation, migration and invasion of NSCLC cells by regulating miR-374a/b-5p/CADM2, miRNA-23a-3p/PTEN and miR-629-5p/TXNIP axis and up-regulating RECK and cytokine signaling 1 in combination with miR-25 and miR-15583 (Hao and Yang 2019 ; He et al 2020 ; Li et al 2020 ). However, the lncRNA ZFAS1, which regulates NSCLC cell proliferation through ZFAS1/miR-590-3p axis, was found to be downregulated in TEPs of NSCLC patients (Luo et al 2018 ; Zhou et al 2020 ). This may be influenced by factors from different gene sources, and the same gene may exhibit different expression trends in pathological tissues and TEPs.…”

Section: Clinical Application Of Tepsmentioning

confidence: 99%

TEP RNA: a new frontier for early diagnosis of NSCLC

Wang,

Dong,

Jin

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (LC), which is the leading cause of tumor mortality. In recent years, compared with tissue biopsy, which is the diagnostic gold standard for tumor diagnosis, Liquid biopsy (LB) is considered to be a more minimally invasive, sensitive, and safer alternative or auxiliary diagnostic method. However, the current value of LB in early diagnosis of LC is not ideal, so it is particularly important to study the changes in blood composition during the process of tumorigenesis and find more sensitive biomarkers. Purpose Platelets are a type of abundant blood cells that carry a large amount of RNA. In the LC regulatory network, activated platelets play an important role in the process of tumorigenesis, development, and metastasis. In order to identify predictive liquid biopsy biomarkers for the diagnosis of NSCLC, we summarized the development and function of platelets, the interaction between platelets and tumors, the value of TEP RNA in diagnosis, prognosis, and treatment of NSCLC, and the method for detecting TEP RNA of NSCLC in this article. Conclusion The application of platelets in the diagnosis and treatment of NSCLC remains at a nascent stage. In addition to the drawbacks of low platelet count and complex experimental processes, the diagnostic accuracy of TEP RNA-seq for cancer in different populations still needs to be improved and validated. At present, a large number of studies have confirmed significant differences in the expression of TEP RNA in platelets between NSCLC patients and healthy individuals. Continuous exploration of the diagnostic value of TEP RNA in NSCLC is of utmost importance. The integration of NSCLC platelet-related markers with other NSCLC markers can improve current tumor diagnosis and prognostic evaluation systems, providing broad prospects in tumor screening, disease monitoring, and prognosis assessment.

show abstract

Long Noncoding RNA ZFAS1 Promotes Progression of NSCLC via Regulating of miR-590-3p

Cited by 10 publications

References 26 publications

The miR-590-3p/CFHR3/STAT3 signaling pathway promotes cell proliferation and metastasis in hepatocellular carcinoma

The miR-590-3p/CFHR3/STAT3 signaling pathway promotes cell proliferation and metastasis in hepatocellular carcinoma

SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma

TEP RNA: a new frontier for early diagnosis of NSCLC

Contact Info

Product

Resources

About